CME Presentations

TROP-2 Lung Cancer


Presentations


Speakers

  • Edward Garon, MD

    Edward Garon, MD

    Edward Garon, MD

    Associate Professor of Medicine

    Edward Garon, MD, is director of the Thoracic Oncology Program at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles (UCLA). He has been the principal investigator of peer reviewed grants from various funding organizations, including the National Institute of Health. Dr Garon’s focus is on clinical research and biomarker development. He has served as the principal investigator on national and international phase I, II and III clinical trials, including trials that have led to the approval of multiple drugs and a companion diagnostic. Dr Garon earned his master’s in clinical investigation from UCLA and his medical degree from Washington University in St. Louis, Missouri.
  • Aaron Lisberg, MD

    Aaron Lisberg, MD

    Aaron Lisberg, MD

    Hematologist and Medical Oncologist

    Aaron Lisberg, MD, is a medical oncologist and assistant professor of medicine at the David Geffen School of Medicine at University of California, Los Angeles (UCLA). He conducts translational research aimed at identifying novel therapeutic approaches for the treatment of thoracic malignancies and has experience as the principal investigator on multiple clinical trials in thoracic oncology. Dr Lisberg has published multiple peer-reviewed manuscripts and presented his research at numerous scientific meetings. He was the recipient of the prestigious LUNGevity Career Development Award in 2019 and recently found out that he has been awarded the American Cancer Society Clinical Scientist Development Grant, as well as a K08 Mentored Clinical Scientist Research Career Development Award.

CME Information

TROP2 Expression: An Evolving Targeted Approach for Patients with Advanced NSCLC


PIM LogoPQH Logo

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:
  • Describe TROP2 as a biomarker, prognostic indicator, and drug target for NSCLC
  • Evaluate the impact of overexpression and upregulation of TROP2 in NSCLC
  • Summarize the unique design principles of ADC anti-TROP2 therapies
  • Compare and contrast the mechanism of action for novel anti-TROP2 therapies
  • Review current clinical trials evaluating anti-TROP2 ADCs in solid tumor cancers, including NSCLC
Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC.

ACKNOWLEDGEMENT

This activity is supported by educational grants from Daiichi Sankyo.

TUITION

Complimentary

JointlyAccreditedProvider Logo

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

LIVE CREDIT DESIGNATION STATEMENTS

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ENDURING CREDIT DESIGNATION STATEMENTS

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DATE OF RELEASE/EXPIRATION

Live Activity

September 1, 2020
• 3:00pm – 4:00pm EST: TROP2 Expression: An Evolving Targeted Approach for Patients with Advanced NSCLC

Enduring Material

The enduring material will be available from September 1, 2020 – September 1, 2021.

TARGET AUDIENCE

Thoracic and medical oncologists, pulmonologists, pathologists, NPs and Pas, oncology nurses and other HCPs involved in the care of patients with lung cancer.

ESTIMATED TIME TO COMPLETE

This activity consists of 1 session which should take approximately 1 hour to complete.

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To participate in the activity, go to www.OMedLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Edward Garon, MD Consulting Fees: GSK, Novartis, Merck
Contracted Research: AZ, BMS, Merck, EMD Serono,Eli Lilly, Novartis, Genentech, Mirati, Neon, Iovance
Aaron Lisberg, MD Consultant/Advisory Board Fees: AstraZeneca, Bristol-Myers Squibb, Leica Biosystems, Jazz Pharmaceuticals, Novocure, Pfizer, MorphoSys
Commercial Research Grants: Daiichi Sankyo, Calithera, Biosciences, AstraZeneca, Dracen Pharmaceuticals, WindMIL

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Tariqa Ackbarali
Medical Director
PlatformQ Health Education, LLC
None
Bridget Griffin
Program Manager
PlatformQ Health Education, LLC
None

The PIM planners and managers have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Bridget Griffin, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support: Please contact the Postgraduate Institute for Medicine at www.pimed.com.

Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.